Amgen Inc. (NASDAQ:AMGN) Shares Sold by Natixis

Natixis decreased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 83.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,978 shares of the medical research company's stock after selling 58,754 shares during the quarter. Natixis' holdings in Amgen were worth $3,122,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Amgen during the third quarter worth about $1,588,000. Morse Asset Management Inc acquired a new position in Amgen during the third quarter worth about $806,000. Tudor Financial Inc. purchased a new stake in Amgen during the 3rd quarter valued at about $3,281,000. World Investment Advisors LLC lifted its stake in Amgen by 48.4% in the 3rd quarter. World Investment Advisors LLC now owns 11,083 shares of the medical research company's stock worth $3,571,000 after purchasing an additional 3,616 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new position in shares of Amgen during the 3rd quarter worth approximately $408,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of Amgen stock traded up $1.00 on Friday, hitting $280.84. The stock had a trading volume of 1,994,531 shares, compared to its average volume of 2,786,220. The company's 50 day moving average price is $301.75 and its 200 day moving average price is $293.08. The stock has a market cap of $150.99 billion, a price-to-earnings ratio of 37.20, a P/E/G ratio of 2.63 and a beta of 0.59. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.39%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is presently 126.09%.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMGN. UBS Group raised their target price on Amgen from $315.00 to $319.00 and gave the stock a "neutral" rating in a research note on Monday, April 14th. Truist Financial decreased their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Piper Sandler increased their target price on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Citigroup restated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Cantor Fitzgerald started coverage on shares of Amgen in a report on Tuesday. They issued a "neutral" rating and a $305.00 target price for the company. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.